RxDoctor Payments Data

Catherine Garcia, MD

Rheumatology · Boynton Beach, FLNPI 1124317821

Payments from drug & device makers

$25,051in general payments, 2019–2025

Across 1,367 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AbbVie$3K
  • Johnson & Johnson$3K
  • UCB, Inc.$2K
  • Novartis$2K
  • GSK$1K
  • plus $9K from 32 others

What the payments were for

  • Food & beverage$24,62398%
  • Education$4282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,051 in reported general payments places this provider in the 65th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$1,566,682
Medicare patients
566
Services billed
109,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel MiniEtanercept20$225,977
Humira(Cf) PenAdalimumab18$168,753
Orencia ClickjectAbatacept27$141,410
OtezlaApremilast29$140,517
Enbrel SureclickEtanercept12$85,829
KevzaraSarilumab19$83,419
ForteoTeriparatide19$81,745
ActemraTocilizumab26$49,309
TymlosAbaloparatide15$43,500
Evenity (2 Syringes)Romosozumab-Aqqg11$27,751
Hydroxychloroquine Sulfate173$5,850
MethotrexateMethotrexate Sodium200$5,788
Colchicine71$3,635
Prednisone455$3,310
Duloxetine Hcl54$2,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Evenity (2 Syringes)$4,479$168,26840 claims
SanofiKevzara$100$83,41919 claims
Lilly USA, LLCForteo$787$81,74519 claims
Radius Health, Inc.Tymlos$1,029$43,50015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →